Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

37
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
37
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.2K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

761
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
761
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

76
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
76
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

7.4K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
7.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

92
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
92

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroinflammation in Epilepsy: Biochemical and Molecular Mechanisms and Implications for Natural Product-Driven Drug Discovery.

International journal of molecular sciences·2026
Same author

Anti-inflammatory potential of the CISACN adduct in LPS-induced murine models.

Inflammopharmacology·2026
Same author

Ribifolones A-H, New Macrocyclic Diterpenes from <i>Jatropha ribifolia</i>, Their Cytotoxic Activity and Insights Supported by Network Pharmacology and Molecular Modeling.

Molecules (Basel, Switzerland)·2026
Same author

A Review of Pathophysiology and Computational Studies of Isoeugenol Derived Acetamides against Alzheimer's Disease.

Current topics in medicinal chemistry·2026
Same author

Antinociceptive Effect of Cinnamaldehyde in Male Mice: Investigation of the Mechanisms of Action Through In Silico and In Vivo Approaches.

Chemistry & biodiversity·2026
Same author

IRACEMA: A Database Management System for Bioactive Compounds Obtained and Characterized by Brazilian Researchers.

ACS omega·2026

Related Experiment Video

Updated: Mar 25, 2026

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes
09:32

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes

Published on: February 13, 2019

16.5K

Multi-Target Drugs for Neglected Diseases.

Luciana Scotti1, Francisco J B M Filho, Ricardo O de Moura

  • 1Health Sciences Center, Federal University of Paraíba, Campus I, 58051-970, João Pessoa, PB, Brazil. luciana.scotti@gmail.com.

Current Pharmaceutical Design
|February 25, 2016
PubMed
Summary

Multi-target drugs offer a promising new approach to combat neglected tropical infections, AIDS, and tuberculosis. These innovative therapies aim for greater effectiveness and safety by targeting multiple disease pathways simultaneously.

More Related Videos

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.9K
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

615

Related Experiment Videos

Last Updated: Mar 25, 2026

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes
09:32

Protocols for Testing the Toxicity of Novel Insecticidal Chemistries to Mosquitoes

Published on: February 13, 2019

16.5K
In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing &#946;-galactosidase
08:48

In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase

Published on: November 5, 2021

3.9K
Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds
07:14

Ookluc: A Plasmodium berghei Line for Identifying Transmission-blocking Compounds

Published on: July 11, 2025

615

Area of Science:

  • Drug discovery and development
  • Medicinal chemistry
  • Infectious diseases

Background:

  • Neglected tropical infections, AIDS, and tuberculosis disproportionately affect underserved populations.
  • Current treatments are often ineffective, lead to drug resistance, and are difficult to access.
  • Limited pharmaceutical investment in neglected diseases due to poor financial returns.

Purpose of the Study:

  • To review major neglected diseases, including AIDS and tuberculosis.
  • To explore research on multi-target drugs for these conditions.
  • To identify new lead compounds for combating infections via multiple routes.

Main Methods:

  • In silico drug design and analysis
  • Chemical synthesis and structural determination
  • Experimental assays for drug efficacy and safety

Main Results:

  • Single compounds targeting multiple pathways may offer simpler development and improved safety.
  • Synergistic action on different targets can enhance drug effectiveness.
  • Emergence of resistant strains and side effects remain challenges.

Conclusions:

  • Multi-target drugs represent a novel strategy for developing new therapeutic agents.
  • Ligands targeting two or more disease-related molecules show potential for combating infections.
  • This approach offers a new avenue for drug discovery against challenging diseases.